Stock Analysis on Net
Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 7, 2024.

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Paying user area

Try for free

Moderna Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Moderna Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Accounts payable
Provisions related to product sales
Compensation-related
Clinical trials
Manufacturing
Development operations
Other external goods and services
Royalties
Property, plant and equipment
Loss on future firm purchase commitments
Commercial
Raw materials
Accrued liabilities
Deferred revenue
Income taxes payable
Financing lease liabilities, current
Operating lease liabilities, current
Other
Other current liabilities
Current liabilities
Deferred revenue, non-current
Operating lease liabilities, non-current
Financing lease liabilities, non-current
Other non-current liabilities
Non-current liabilities
Total liabilities
Preferred stock, $0.0001; no shares issued or outstanding
Common stock, par value $0.0001
Additional paid-in capital
Accumulated other comprehensive income (loss)
Retained earnings (accumulated deficit)
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Moderna Inc. current liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Moderna Inc. non-current liabilities increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Moderna Inc. total liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Moderna Inc. stockholders’ equity increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.